?
open question

Patient selection**: Which patients are most likely to benefit from LRRK2-targeted therapies?

Open Question open Wiki: entities-lrrk2
Patient selection**: Which patients are most likely to benefit from LRRK2-targeted therapies?
Importance Elo
1500
Field Rank
Rank #61 in entities
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page entities-lrrk2
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD
candidate answer · experiment · 82%
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
partial answer for · experiment · 45%
AAV Serotype Comparison for LRRK2 Knockdown in PD
partial answer for · experiment · 45%
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
partial answer for · experiment · 45%
AAV-LRRK2 IND-Enabling Study Design
bears on question · experiment · 40%
AAV-LRRK2 Gene Therapy IND-Enabling Study Design
bears on question · experiment · 40%
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
entities
View on SciDEX ↗